Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer

Q3 Medicine

Cancer treatment and research communications Pub Date : 2023-01-01 DOI:10.1016/j.ctarc.2023.100713

Idoko Salifu , Navneet Singh , Maria Berraondo , Jordi Remon , Stephanie Salifu , Eric Severson , Angela Quintana , Sandra Peiró , Shakti Ramkissoon , Laura Vidal , Isagani Chico , Kamal S. Saini

{"title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer","authors":"Idoko Salifu , Navneet Singh , Maria Berraondo , Jordi Remon , Stephanie Salifu , Eric Severson , Angela Quintana , Sandra Peiró , Shakti Ramkissoon , Laura Vidal , Isagani Chico , Kamal S. Saini","doi":"10.1016/j.ctarc.2023.100713","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immune checkpoint inhibitors (ICIs) for patients with aNSCLC.</p></div><div><h3>Areas covered</h3><p>Due to the demonstrated efficacy of ADCs and ICIs in aNSCLC, treatment combining both agents merits attention. This article, therefore, explores the use of ADCs and ICIs in patients with NSCLC, assesses the scientific rationale for combination treatment, and provides an overview of ongoing trials. It also presents some early efficacy and safety results of such combination use.</p></div><div><h3>Expert opinion</h3><p>It is not clear whether ADC-immunotherapy has a significant impact on those with a targetable oncogenic driver alteration since targeted therapies are effective. However, in aNSCLC without a targetable oncogenic driver alteration, the combination of ADCs and ICIs has potential and remains an area of active clinical research.</p></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment and research communications","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2468294223000345","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction

Advanced non-small cell lung cancer (aNSCLC) is an incurable disease. The effort to develop treatments with more effective systemic agents continues. This has led to the FDA approval of one antibody–drug conjugate (ADC) and eight immune checkpoint inhibitors (ICIs) for patients with aNSCLC.

Areas covered

Due to the demonstrated efficacy of ADCs and ICIs in aNSCLC, treatment combining both agents merits attention. This article, therefore, explores the use of ADCs and ICIs in patients with NSCLC, assesses the scientific rationale for combination treatment, and provides an overview of ongoing trials. It also presents some early efficacy and safety results of such combination use.

Expert opinion

It is not clear whether ADC-immunotherapy has a significant impact on those with a targetable oncogenic driver alteration since targeted therapies are effective. However, in aNSCLC without a targetable oncogenic driver alteration, the combination of ADCs and ICIs has potential and remains an area of active clinical research.

查看原文本刊更多论文

抗体驱动的偶联物、免疫检查点抑制剂及其联合治疗晚期癌症

简介晚期癌症是一种不可治愈的疾病。开发更有效的全身药物治疗方法的努力仍在继续。这导致美国食品药品监督管理局批准了一种抗体-药物偶联物（ADC）和八种免疫检查点抑制剂（ICIs）用于非小细胞肺癌患者。涵盖的领域由于ADC和ICIs在非小细胞肝癌中的疗效已得到证实，将两种药物联合治疗值得关注。因此，本文探讨了ADC和ICIs在NSCLC患者中的应用，评估了联合治疗的科学原理，并对正在进行的试验进行了概述。它还介绍了这种联合使用的一些早期疗效和安全性结果。专家意见目前尚不清楚ADC免疫疗法是否对那些有靶向致癌驱动因素改变的人有显著影响，因为靶向疗法是有效的。然而，在没有靶向致癌驱动因素改变的NSCLC中，ADC和ICIs的组合具有潜力，并且仍然是一个积极的临床研究领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer treatment and research communications Medicine-Oncology

CiteScore

4.30

自引率

0.00%

发文量

148

审稿时长

56 days

期刊介绍： Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research. The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists. Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types. The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials. Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches. Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.